Introduction
Locally advanced rectal cancer has been reported to have high rates of local recurrence after surgical resection alone. 1) In 1990, a National Institutes of Health consensus conference recommended postoperative adjuvant chemoradiotherapy for patients with Stage II or III rectal cancer. 2) A large randomized control study showed that preoperative concurrent chemoradiotherapy (CCRT) was superior to postoperative CCRT in terms of local control and toxicities, although there was no difference in the disease-free and overall survival rate. 3) As a result, preoperative CCRT has become a standard component of multimodal treatment for patients with locally advanced rectal cancer.
Hyperthermia (HT), known as a potent radiosensitizer, has been shown to increase not only the response rates, but also clinical outcomes to radiotherapy (RT) in various cancers, including rectal cancer. [4] [5] [6] Two randomized trials comparing preoperative RT to hyperthermoradiotherapy in locally advanced rectal cancer reported no significant difference of acute toxicity. 7, 8) Recently HT has been combined with CCRT to increase the response and several pilot to phase II studies also reported that HT could be safely combined with preoperative CCRT in locally advanced rectal cancer. [9] [10] [11] [12] However, there are few reports about the late complications after surgery following preoperative hyperthermo(chemo)radiotherapy in locally advanced rectal cancer despite the long-term use of HT. In addition, most studies on complications were conducted using the BSD-2000 system (BSD Medical Corporation, Salt Lake City, Utah, USA); recently in Korea, capacitive type machines are being increasingly used.
Thus, we retrospectively analyzed the impact of HT using a capacitive type machine on postoperative complications in locally advanced rectal cancer treated with preoperative CCRT followed by curative surgery.
Materials and Methods

Patients
We previously reported the clinical outcomes of 235 patients with histologically-confirmed, locally advanced rectal adenocarcinoma (cT3-4 or N+), who completed preoperative CCRT with or without HT followed by curative resection from 1996 to 2007 [6] . Only tumors located within 10 cm from the anal verge were included. Patients with metachronous or synchronous double primary cancers, rectosigmoid or sigmoid tumors (above 10 cm from the anal verge), early distal rectal tumors (cT1-2N0), or distant metastasis at the time of diagnosis or at the time of surgery were excluded.
In this study, 205 patients who were evaluable for acute and late toxicities after surgery were analyzed. Patients with a follow-up period of less than 6 months after surgery (n=12) or who had previous abdominal surgery history (n=5) or who received postoperative RT (n=13) were excluded.
Treatment
Radiotherapy was delivered to the whole pelvis with three or four fields in a prone position. The total dose of RT was 39.6 Gy or 45 Gy with a daily dose of 1.8 Gy over 5 weeks.
Chemotherapy commenced concurrently with RT, and a total of 2∼3 cycles of chemotherapy were administered before sur- 
Complications
Complications were evaluated through medical records, including physical examinations, colonofiberscopy and diagnostic images. Early leakage was defined as leakage that occurred within one month after surgery and delayed anastomotic leakage was defined as leakage thereafter. An anastomotic stricture was considered to be present when it was not possible to traverse the anastomosis site with a flexible colonofiberscope. As to small bowel obstruction, complications that required hospitalization or more serious ones were recorded regardless of the causes. Complication profiles of patients with locoregional failures were investigated during the disease-free period. The median follow-up period from the date of surgery to the last hospital follow-up was 59 months (range, 2∼188 months) and 70.5 months (range, 10∼179 months), respectively.
Statistics
Patients were classified into the non-HT or HT group according to the use of HT. Categorical variables were compared with the chi-square test or Fisher's exact test, and continuous ones with the student t-test for a comparison of the two groups. The survival rate was calculated from the first day of CCRT to the date of the event using the Kaplan-Meier method. 
Results
The median age was 59 years (range, 18∼83 years). The patient and tumor characteristics except gender distribution
were not different in both groups ( Table 1 ). The mean distance from anal verge to tumor was not different in both groups (6.3∼2.9 cm in non-HT group vs. 6.4∼2.8 cm in HT group, p=0.940).
The 5-year overall, disease free, locoregional relapse-free and distant metastasis-free survival rates of all patients was 77.4%, 75.2%, 93.8% and 78.8%, respectively (Fig. 1) .7) 0.694 Table 3 . Ileostomy or colostomy status in patients who received sphincter preservation surgery. HT group, p=0.556); of these, 25 patients received reduction surgery thereafter. Colostomy was performed newly on ten patients due to complications (8 in non-HT vs. 2 in HT group).
Finally, the number of patients without ileostomy or colostomy was similar in both groups at the last follow-up (79.2% of non-HT group and 76.7% in HT group, p=0.694).
Discussion
Chemotherapy is concurrently used with radiotherapy in locally advanced rectal cancer because it could increase the response and local control rates without increasing postoperative morbidity and anastomotic leak rates. 13) Recently, HT has been attempted to be combined with CCRT in locally advanced rectal cancer; however there is little information about the potential postoperative complications after hyperthermochemoradiotherapy. However, this study showed that HT did not increase the postoperative complications after CCRT.
Van der Zee et al. 8) reported the results of the phase III study, comparing RT with and without HT in locally advanced cervical, rectal and bladder cancer. A total of 358 patients were enrolled. In primary or recurrent rectal cancer patients, a total dose of 46∼50 Gy with or without a boost of 10∼24
Gy was delivered. HT was given once weekly during the period of RT. In all patients, acute grade 3∼4 radiation-related toxicities were seen in 4% of patients (2.2% in RT+HT group vs. 5.9% in RT group). The actuarial cumulative incidence of grade 3∼4 toxic effects at 2 years was 12% in each group.
Although detailed toxicity profiles were not described, the acute and late toxicities did not differ according to the use of HT.
Schulze et al. 14) reported The early anastomotic leakage rate after sphincter-saving resection has been reported as 3∼20%. [15] [16] [17] Kim et al. 18) re- al. 14) reported that the insufficiency of anastomosis occurred in 10% of patients and its development was not influenced by the use of HT in a phase II/III trial comparing preoperative CCRT alone to HT.
Small bowel obstruction is believed to occur less frequently after preoperative RT when compared to postoperative RT.
Kim et al. 18) reported that small bowel obstruction related to radiation enteritis was more frequent in patients treated with postoperative CCRT when compared to those treated with preoperative CCRT (1.4% vs. 0%, p=0.042). In the current study,
HT did not increase the frequency of small bowel obstruction with any causes when combined with preoperative CCRT (17.1%
vs. 17%, p=993). Schulze et al. 14) reported that ileus occurred in 11% of patients, where HT also did not influence its development after surgery following preoperative CCRT.
Horie et al. 19) retrospectively compared the outcomes of 29 patients who underwent preoperative CCRT±HT followed by curative surgery for lower rectal cancer. A total dose of 40.5
Gy ( Recently, quality of life (QoL) as well as treatment outcome has been considered to be important in decision making. Schulze et al. 14) reported the quality of life as well as toxicities in locally advanced rectal cancer patients treated with preoperative CCRT with or without HT. QoL was assessed four times using the Gasrointestinal Quality-of-life Index 20) ; before the start of preoperative CCRT (mean: 88±2 days before surgery), after the end of the CCRT (mean: 9±2 days before surgery), early after the surgery (mean: 53±4 days after surgery) and during the long-term follow-up (mean: 849±77 days after surgery).
Although the domains 'Symptoms', 'Physical functions', 'Social life' and 'Medical treatment' at the end of the CCRT seemed to be worse in the HT group, HT did not result in a significant reduction of QoL. In the long-term follow-up, both groups reported equally good QoL scores.
Conclusions
Regional HT did not increase postoperative complications in locally advanced rectal cancer treated with preoperative CCRT.
However, the retrospective nature of this study and the rarity of the results of large prospective studies limit the definite conclusions regarding the complications of HT combined with preoperative CCRT; hence a prospective randomized controlled trial is warranted.
